<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03674099</url>
  </required_header>
  <id_info>
    <org_study_id>Imatinib MS</org_study_id>
    <nct_id>NCT03674099</nct_id>
  </id_info>
  <brief_title>Imatinib for Multiple Sclerosis (MS) Relapses</brief_title>
  <official_title>Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomas Olsson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Swedish Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate if treatment with Imatinib results in a better outcome than standard care in
      form of Methylprednisolone(MP) after MS-associated relapses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, single-blinded, controlled.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Treating physician not blinded, evaluating physician blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Functional system score (FSS) change in the most worsened FSS after 28 days due to the acute relapse</measure>
    <time_frame>28 days</time_frame>
    <description>The primary endpoint is mean change between baseline and day 28 in the most worsened FSS due to the acute relapse comparing MP and Imatinib. In case more than one domain is affected, priority of selected FSS should be in the following order: 1) Pyramidal, 2) Brain stem, 3) Cerebellar, 4) Visual, 5) Sensory. At least a two step deterioration due to neuroinflammatory bout should have occurred. Bowel and Cerebral domains will not be considered in the primary endpoints. The FSS is graded accordingly: 1. Visual function. Grade 0-6 2. Brain stem function grade 0-5 3. Pyramidal function, grade 0-6 4. Cerebellar function, grade 0-5 5. Sensory function grade 0-6 6. bowel/bladder function 7. Cerebral functions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional system score (FSS) change between baseline and week 12 in the most worsened FSS due to the acute relapse</measure>
    <time_frame>12 weeks</time_frame>
    <description>In case more than one domain is affected, priority of selected FSS should be in the following order: 1) Pyramidal, 2) Brain stem, 3) Cerebellar, 4) Visual, 5) Sensory. At least a two step deterioration due to neuroinflammatory bout should have occurred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean expanded disability status scale (EDSS) change between baseline and day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Calculation of EDSS summary score is based on the FSS score, from 0-5 with 0 representing normal neurological exam and 10 representing death by MS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in 9-hole peg test (evaluates upper limb function) between baseline and day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluates upper limb function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in timed 25- walk between baseline and day 28</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in symbol digital modality test (SDMT) between baseline and day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluates cognitive function, with a score range of 0 to 110, with 110 representing the best cognitive function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Multiple Sclerosis Impact Scale (MSIS-29; MS-specific quality of life (QoL) scale) between baseline and day 28</measure>
    <time_frame>28 days</time_frame>
    <description>The MISIS-29 consists of 29 items (composed of 20- item physical scale and a 9-item psychological scale), graded from 1-5 points with 5 indicating the most severe impact. The points for the two scales are individually summarized. The physical scale results in a sum with a range 20-100 , where 100 indicates the worse health. The psychological scale is similarly resulting in a range between to 9- 45, where 9 is the least and 45 is the worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in EQ5D (EuroQol 5 dimensions) (general QoL) between baseline and day 28.</measure>
    <time_frame>28 days</time_frame>
    <description>EQ-5D is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any difference in number of new brain MRI lesions at day 14 with regards to the baseline, comparing the two drugs</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any difference in number of new brain MRI lesions at day 28 with regards to the baseline, comparing the two drugs</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Imatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imatinib will be administered orally one tablet (400mg) twice daily, 800mg per day for 14 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methylprednisolone will be administered once a day either in tablets; Medrol 1g per day or iv; Solumedrol 1000 mg per day, both for three consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib Mesylate</intervention_name>
    <description>Tablets 400 mg</description>
    <arm_group_label>Imatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>1 g tablets or infusion</description>
    <arm_group_label>Methylprednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An acute exacerbation, relapse, in persons with RRMS, either newly diagnosis or on
             treatment with one of the long-term immunomodulatory drugs, or possible MS where the
             diagnosis is supported by typical MRI or cerebrospinal fluid changes typical of MS
             (this enables inclusion of persons with a first neuroinflammatory bout, with high risk
             of developing MS before fulfilling the McDonald criteria for definite MS, or high risk
             for developing MS in the category clinically isolated syndrome (CIS)/possible MS with
             supporting MRI lesions and/or cerebrospinal fluid aberrations suggesting intra-thecal
             immunoglobulin synthesis with oligoclonal bands/and/or increased free Kappa Light
             chains. The relapse should be deemed to require relapse treatment by the investigator
             and affect a functional domain with a minimum of grade 2.

          -  18-55 years of age

          -  Affection of any of the following EDSS sub-domains representing the targeted
             neurological deficit: 1. Visual function. grade 0-6, 2. Brain stem function grade 0-5.
             3. Pyramidal function, grade 0-6. 4. Cerebellar function, grade 0-5. 5. Sensory
             function grade 0-6, and deterioration at least one step in any of these EDSS domains

          -  EDSS ≤ 6 before the acute exacerbation

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, if they are using effective methods of contraception during the
             study. Acceptable birth control methods are those with a failure rate of less than 1%
             per year when used consistently and correctly according to CTFG, September 2014
             &quot;Recommendations related to contraception and pregnancy testing in clinical trials&quot;.
             Such methods include:

               1. Combined (estrogen and progestogen containing hormonal contraception associated
                  with inhibition of ovulation.

                    -  oral

                    -  intravaginal

                    -  transdermal

               2. progestogen-only hormonal contraception associated with inhibition of ovulation

                    -  oral

                    -  injectable

                    -  implantable

               3. intrauterine device (IUD)

               4. intrauterine hormone-releasing system (IUS)

               5. bilateral tubal occlusion

               6. total abstinence or vasectomized partner.

        Exclusion Criteria:

          -  A pseudo-relapse should be excluded, as deemed by the experienced treating
             neurologist, and as evidenced by an active infection, likely with fever, with
             reappearing new signs and symptoms in a previously affected neurological function.

          -  Inability to provide informed consent

          -  Concomitant medication with drugs which may increase the plasma concentration of
             Imatinib - ketoconazole, itraconazole , erythromycin and clarithromycin

          -  Concomitant medication with drugs which may decrease the plasma concentration of
             Imatinib: dexamethasone, phenytoin, carbamazepin, rifampicin, phenobarbital,
             fosphenytoin, primidon, Hypericum perforatum (St John's wort).

          -  Female patients with childbearing potential, if pregnancy cannot be excluded by
             pregnancy test (urine point-of-care pregnancy test).

          -  Patient is participating in other interventional study

          -  General infection or any other condition judged by the treating neurologist to
             contra-indicate Imatinib

          -  Any laboratory deviation of general bodily functions such as kidney, or renal function
             judged to be of clinical significance by the treating neurologist constitutes an
             exclusion criteria.

          -  Patients with a positive Hepatitis B-DNA test result or serology indicating latent
             infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tomas Olsson, MD, Prof</last_name>
    <phone>+46707213598</phone>
    <email>Tomas.Olsson@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FinnThorup Sellebjerg, MD</last_name>
      <email>finn.thorup.sellebjerg@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland sjukhus</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kjell Morten Myhr, MD</last_name>
      <email>kjell-morten.myhr@helse-bergen.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trygve Holmöy, MD</last_name>
      <email>trygve.holmoy@medisin.uio.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet, Oslo</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanne Flinstad Harbo, MD</last_name>
      <email>h.f.harbo@medisin.uio.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ullevåls sjukhus</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabeth G Celius, MD</last_name>
      <email>uxelgu@ous-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Universityhospital, Huddinge</name>
      <address>
        <city>Huddinge</city>
        <state>Stockholm</state>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharina Fink, MD</last_name>
      <email>Katharina.Fink@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurology Sahlgrenska Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Lycke, MD</last_name>
      <email>jan.lycke@neuro.gu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charlotte Dahle, MD</last_name>
      <email>Charlotte.Dahle@regionostergotland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akademiskt specialistcentrum</name>
      <address>
        <city>Stockholm</city>
        <zip>11341</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik Piehl, MD</last_name>
      <phone>+46-851779840</phone>
      <email>Fredrik.Piehl@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset, Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Olsson, MD</last_name>
      <phone>+46707213598</phone>
      <email>Tomas.Olsson@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joachim Burman, MD</last_name>
      <email>joachim.burman@akademiska.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Tomas Olsson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis relaps</keyword>
  <keyword>Imatinib</keyword>
  <keyword>Methylprednisolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

